The Risk and Survival Analysis of Multiple Malignancies in Hematologic Malignancy Patients: A Single Chinese Center Retrospective Study, 2009 through 2017.
10.19746/j.cnki.issn.1009-2137.2023.02.012
- Author:
Xu-Chang ZHANG
1
;
Lei FAN
2
;
Hua LU
2
;
Si-Xuan QIAN
2
;
Li-Juan CHEN
2
;
Wei XU
2
;
Jian-Yong LI
2
;
Xiao-Yan QU
3
;
Xiao-Li ZHAO
4
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu Province, China,Department of Geriatric, Guangdong Longgang District People's Hospital of Shenzhen, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, Guangdong Province, China.
2. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu Province, China.
3. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu Province, China,E-mail: quxiaoyan205@163.com.
4. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu Province, China,E-mail: qiyue3706@163.com.
- Publication Type:Journal Article
- Keywords:
first primary malignancy;
hematologic malignancies;
second primary malignancy;
survival
- MeSH:
Humans;
East Asian People;
Hematologic Neoplasms/complications*;
Lymphoma/complications*;
Multiple Myeloma/complications*;
Neoplasms, Second Primary;
Retrospective Studies;
Survival Analysis
- From:
Journal of Experimental Hematology
2023;31(2):389-395
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the risk and location of multiple malignancies in patients with hematologic malignancies who were followed up for 9 years in Jiangsu Province Hospital and to evaluate the impact of the second primary malignancy on survival of patients.
METHODS:The incidence and survival of multiple malignancies in 7 921 patients with hematologic malignancies from 2009 to 2017 were analyzed retrospectively.
RESULTS:A total of 180 (2.3%, 180/7 921) patients developed second malignancy, of whom 58 patients were diagnosed with hematologic malignancies as the first primary malignancy, and 98 patients developed hematologic malignancies as second primary malignancy, and the other 24 cases were diagnosed with the second malignancy within 6 months after the first primary malignancy was diagnosed, which was difined as multiple malignancies occurring simultaneously. In 180 patients, 18 cases developed two hematologic malignancies successively, and 11 patients developed more than 3 primary cancers (among them, 2 female patients were diagnosed with 4 primary cancers). Patients with lymphoma and multiple myeloma (MM) as the second primary malignancy had poorer survival than patients with lymphoma and MM as the first primary malignancy. Patients with chronic myeloid leukemia as the second primary malignancy were also associated with inferior overall survival.
CONCLUSION:In this study, 2.3% of hematologic malignancy patients had multiple mali-gnancies, lymphoma and MM as the second primary malignancy had poor survival.
